A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors.
Wang T, Wang D, Yu H, Feng B, Zhou F, Zhang H, Zhou L, Jiao S, Li Y. · 2018
Read A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors. by Wang T, Wang D, Yu H, Feng B, Zhou F, Zhang H, Zhou L, Jiao S, Li Y. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5906566.txt.
Introduction
Wang and co-authors present a cancer vaccine for use after surgery. Their article appeared in Nature Communications. Leftover tumour cells can cause relapse and spread. The vaccine, called PVAX, uses a patient's own tumour cells. Those cells carry two added agents inside a hydrogel. One agent blocks a growth protein, the other aids light activation.
Near-infrared light triggered the vaccine in their tests, they report. It matured dendritic cells and drew killer T cells in. Antigen release and checkpoint blocking worked together. Memory responses formed against the patient's own tumour. Relapse was strongly held back in the model. Readers get a plan for personal post-surgery therapy.
Catalog record
| CREATOR | Wang T, Wang D, Yu H, Feng B, Zhou F, Zhang H, Zhou L, Jiao S, Li Y. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 58 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors By Tingting Wang, Dangge Wang, Haijun Yu, Bing Feng, Fangyuan Zhou, Hanwu Zhang, Lei Zhou, Shi Jiao, Yaping Li Published in: Nature Communications DOI: 10.1038/s41467-018-03915-4 ABSTRACT Abstract Vaccines to induce effective and sustained antitumor immunity have great potential for postoperative cancer therapy. However, a robust cancer vaccine simultaneously eliciting tumor-specific immunity and abolishing immune resistance continues to be a challenge. Here we present a personalized cancer vaccine (PVAX) for postsurgical immunotherapy. PVAX is developed by encapsulating JQ1 (a BRD4 inhibitor) and indocyanine green (ICG) co-loaded tumor cells with a hydrogel matrix. Activation of PVAX by 808 nm NIR laser irradiation significantly inhibits the tumor relapse by promoting the maturation of dendritic cells and eliciting tumor infiltration of cytotoxic T lymphocytes. A mechanical study reveals that NIR light-triggered antigen release and JQ1-mediated PD-L1 checkpoint blockade cumulatively contribute to the satisfied therapeutic effect. Furthermore, PVAX prepared from the autologous tumor cells induces patient-specific memory immune response to prevent tumor recurrence and metastasis. The PVAX model might provide novel insights for postoperative immunotherapy. INTRODUCTION Surgical resection is the primary option for clinical treatment of early stage and nonmetastatic solid tumors. However, residual microtumors or circulating tumor cells (CTCs) may cause lethal tumor recurrence and metastasis for months or years postoperation1, 2. Neoadjuvant chemotherapy and radiotherapy are the current standard-of-care for post-surgical cancer management, they both tend to decrease the life quality of patients3. Alternatively, approaches utilizing cancer immunotherapy have emerged for tumor regression and metastasis prevention by stimulating the host immune response4–10. Immunotherapy using peptide-based vaccines or checkpoint inhibitors has induced durable clinical response in several types of tumors including melanoma, lung and bladder cancers11, 12. The recent innovation in cancer exome sequencing has further promoted the development of patient-specific neoantigens for personalized immunotherapy13–17. Unfortunately, the objective response rates of peptide-based vaccines have been disappointing in clinical trials due to tumor heterogeneity and their inefficiency to co-deliver multiple antigen peptides and adjuvants to the draining lymph nodes (LNs)7, 18, 19. Furthermore, the sequencing and preparation of patient-derived neoantigens is costly and time consuming, which is unfavorable for metastatic or late-stage cancer patients20. Cancer vaccines developed from whole tumor cells represent a promising avenue for cancer immunotherapy. Identification of the tumor antigens is not necessary for tumor cell vaccine generation since the tumor cells contain the whole array of mutated epitopes for parallel presentation to both CD8+ and CD4+ T cells, which reduces the likelihood of tumor escape21. Moreover, the autologous tumor cell source obtained from patients can release patient-specific antigens to trigger antitumor immunity and achieve personalized immunotherapy22, 23. However, the tumor cell vaccine-initiated immune response is negatively modulated in the intrinsic immunosuppressive tumor microenvironment7, 15, 24–26. Moreover, tumor cell vaccines can induce interferon γ (IFN-γ) secretion, which elicits the expression of programmed death ligand 1 (PD-L1) in the tumor and thus induces adaptive immune resistance27. To address the above issues associated with vaccine-based cancer immunotherapy approaches, we herein propose a personalized cancer vaccine (PVAX) with immune checkpoint blockade capacity for postsurgical immunotherapy of the recurrent and metastatic tumors. PVAX is developed by integrating JQ1 and indocyanine green (ICG) co-loaded tumor cells with a hydrogel matrix (Fig. 1a). JQ1 is a small molecular inhibitor for bromodomain and extraterminal (BET) protein BRD4, which overcomes immune tolerance by suppressing intratumoral expression of PD-L125, 28. ICG is a well-studied photoabsorbent with high photothermal conversion efficiency, which has been widely exploited for photothermal therapy of various solid tumors7, 29, 30. Upon NIR laser irradiation, ICG induces significant temperature elevation to trigger on-demand release of tumor-specific antigens and JQ1. The hydrogel matrix is fabricated with a tumor-penetrable peptide to prevent cargo leakage and facilitate tumor penetration of the tumor vaccines for overcoming tumor burden (Fig. 1b). We demonstrate that administration of the PVAX through local injection followed by NIR laser-triggered activation efficiently prevent postoperative tumor recurrence and metastasis by simultaneously boosting patient-specific immune responses and blocking PD-L1-dependent immune evasion. The simple PVAX fabrication procedure combined with its ability to simultaneously induce a patient-specific immune response, and combat immunological resistance, supports its potential as a robust cancer vaccine for post-surgical immunotherapy. [Figure: Schematic illustration of fabrication of PVAX for cancer immunotherapy. a Fabrication process of PVAX. b Simplified mechanism of PVAX-mediated cancer immunotherapy to prevent post-operative tumor recurrence and metastasis] RESULTS Fabrication of PVAX To fabricate the PVAX for personalized immunotherapy, tumor cells from mouse 4T1 breast tumor xenografts were collected and fixed in a Foxp3 cell fixation and permeabilization buffer. The fixed tumor cells were then incubated in a methanol solution of ICG and JQ1 for 4 h to obtain ICG and JQ1 co-loaded tumor cells (abbr., IQ-4T1). The ICG and JQ1 loading ratios were determined to be ~18.6 ± 0.4 and 26.3 ± 0.7 μg/106 tumor cells using UV–Vis photospectrometry and high-performance liquid chromatography (HPLC) measurements, respectively (datas represent means ± s.d. (n = 3), Supplementary Fig. 1). The IQ-4T1 cells were further encapsulated with a hydrogel matrix to prevent payload leakage. The hydrogel was prepared with a tumor-penetrable peptide sequence of Fmoc-KCRGDK (FK). FK was employed to facilitate tumor penetration of the tumor antigens and JQ1 by binding with neuropilin-1 (Nrp-1), a protein overexpressed on surface of the tumor cells31–33. Two Fmoc groups were grafted on the peptide sequence to stabilize the peptide hydrogel via π–π stack and hydrophobic interaction among the Fmoc groups. The Fmoc groups were modified on the N-terminal of the peptide to avoid impairing the tumor penetration activity of the CRGDK motif. Fmoc-KCRGDC (FC) peptide was also synthesized as an tumor non-penetrable analog of FK for vaccine development (Supplementary Fig. 2, 3). FK peptide formed self-assembled micelles in PBS, which transformed to assembled nanofibers, and to hydrogels after 70 °C incubation for 8.0 min as examined using transmission electron microscopy (TEM) (Fig. 2a and Supplementary Fig. 4a), scanning electron microscopy (SEM) (Fig. 2b and Supplementary Fig. 4b) and optical transmittance measurements (Supplementary Fig. 4c–f). The resultant FK hydrogel was thixotropic and injectable due to the noncovalent crosslinking nature of the self-assembling materials, allowing IQ-4T1 encapsulation through simple mixing, followed by local injection of the cancer vaccines at the surgical bed (Fig. 2c). The IQ-4T1-loaded FK hydrogels (termed as FK@IQ-4T1) displayed similar rheological properties as cell-free hydrogels, indicating encapsulation of tumor cells negligibly affected the mechanical properties of the peptide hydrogels (Fig. 2d and Supplementary Fig. 4g). [Figure: Characterization of PVAX for cancer immunotherapy. a TEM (Scale bar, 100 nm), and b SEM (Scale bar, 20 μm) examination of the tumor cell-loaded FK hydrogel. c Hydrogel encapsulation of ICG and JQ1 co-loaded 4T1 tumor cells (IQ-4T1). d Frequency-dependent rheological properties of pure and FK@IQ-4T1 tumor hydrogels examined at 37 °C (peptide concentration 10 wt%, strain 1%). e NIR laser-triggered JQ1 release profile of FK@IQ-4T1 as a function of photodensity. Data represent means ± s.d. (n = 3). f SDS-PAGE electrophoresis of laser-triggered tumor antigen release from FK@IQ-4T1vaccine, the lysate of whole 4T1 cells was used as a positive control. FK@IQ-4T1 vaccine were illuminated with 808 nm laser for 2 min at the desired photodensity] To determine the distribution of the tumor cells inside the hydrogel matrix, JQ1 was replaced with the fluorescent dye